Subscribe To

Price Alert Latest News Economic Calendar News

PRFX / PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th

TEL AVIV, Israel, March 21, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced it will present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT. Read More

Demo Live Account See Partner Details

Content Topics

Painreform

Present

2022

Virtual

Growth

Conference

Presented

Conference presented

Hosted

M vest

On march

Stock

PRFX

Posted: Mar 21 2022, 09:25

Author Name: GlobeNewsWire

PRFX News

By InvestorPlace
July 20, 2023

Why Is PainReform (PRFX) Stock Up 38% Today?

PainReform (NASDAQ: PRFX ) stock is rallying on Thursday after the pharmaceutical company regained compliance with Nasdaq listing requirements. Accor

By InvestorPlace
July 14, 2023

PRFX Stock: The $2.7 Million Reason PainReform Is Up 100% Today

In the world of biotech stocks, one company that's generating big buzz today is PainReform (NASDAQ: PRFX ). The Israeli clinical-stage pharmaceutical

By InvestorPlace
July 12, 2023

Why Is PainReform (PRFX) Stock Down 40% Today?

PainReform (NASDAQ: PRFX ) stock is falling on Wednesday after the company announced a concurrent registered direct offering and private placement. Th

By InvestorPlace
February 8, 2023

Why Is PainReform (PRFX) Stock Up 48% Today?

PainReform (NASDAQ: PRFX ) stock is rocketing higher on Wednesday following an update on its delisting ordeal. A press release confirms that the compa

By GlobeNewsWire
March 21, 2022

PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th

TEL AVIV, Israel, March 21, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharma

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.